EUWithdrawn

Acomplia

This is a locally preserved regulatory record. Source labeling does not by itself prove efficacy for a condition.

Regulatory product record. The connected regulator reports this product as withdrawn, discontinued or otherwise historical.

Product data

Locally preserved regulatory fields

Active ingredients: rimonabant
Route: Not reported
Dosage form: Not reported
Marketing holder: sanofi-aventis
Catalog status: Withdrawn
Source-reported status: Withdrawn

Medicine name group

2 preserved variants

Records share the same exact normalized name. Different identifiers, strengths, countries, presentations and statuses remain separate.

WithdrawnEUCurrent record

Acomplia

Strength not reported

Route and form not reported

2 identifiers · EMA medicines

Status not establishedEU

ACOMPLIA

Strength not reported

Route and form not reported

1 identifiers · EU Union Register of medicinal products

Linked local records

Related local records

Substance links use source-reported active ingredients. Condition links come from registered study context and are not efficacy claims.

Cannabinoids and active compounds

No governed active-ingredient link was found.

Condition reports

No published condition report matched the registered study context.

Regulatory record

Approval, patents and exclusivity

Patent and exclusivity fields are preserved from the regulator. They are not a legal opinion and are separate from clinical development.

0approval records

0source-reported patents

0exclusivity records

Clinical development

Related registered studies

Phases and statuses are source-reported study stages matched by governed token phrases. They do not prove medicine identity, approval or efficacy.

5candidate study links

PHASE3TERMINATED

Effect of Rimonabant, a Cannabinoid Receptor 1 Antagonist on Weight Gain and Body Composition in Adults With Prader Willi Syndrome.

DRUG · rimonabant

Prader-willi Syndrome

PHASE2COMPLETED

Clinical Trial of the Cannabinoid CB1 Receptor Antagonist, SR141716 (Rimonabant), to Reduce Voluntary Ethanol Drinking in Healthy, Non-Treatment Seeking Individuals Who Consume Between 20 and 50 Drinks Per Week

DRUG · SR141716 (Rimonabant)

Healthy · Alcohol Drinking

PHASE1COMPLETED

Antagonist-Elicited Cannabis Withdrawal

DRUG · Rimonabant

Cannabis · Dependence

PHASE2COMPLETED

Translational Center on the Clinical Neurobiology of Cannabis Addiction

DRUG · rimonabant

Cannabis Dependence · Cannabis Withdrawal

NACOMPLETED

Atherosclerotic Plaque Texture-Experimental and Clinical Study on the Diagnostic and Therapeutic Strategies of Atherosclerotic Plaque Vulnerability

DRUG · rimonabant

Carotid Atherosclerosis · Stroke · Type 2 Diabetes · Metabolic Syndrome

Source-reported use

Indications in regulatory records

As an adjunct to diet and exercise for the treatment of obese patients (BMI 30 kg/m2), or overweight patients (BMI 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).

Medicine identity matching

RxNorm candidates

RxNorm normalizes identity; FAERS supplies non-causal post-market signals.

Identity candidate · score 10.34007453918457

rimonabant

Matched from: rimonabant

Official RxNorm record

Identity candidate · score 6.4052393713716755

RxNorm concept

Matched from: rimonabant

Official RxNorm record

Safety signals

Locally preserved FAERS reports

0reports

0reported as serious

FAERS/AEMS reports are post-market signals. Counts do not establish causality or incidence and may contain duplicates or reporting bias.

Sources and provenance

Official source snapshots

EMA medicines

EMEA/H/C/000666 · version 8

Retrieved 03/08/2026, 16:38:00Verify at source